Prothena data from AD/PD abstract ‘promising,’ says Jefferies

Jefferies analyst Michael Yee noted that AD/PD released some abstracts ahead of their March 2023 conference, including one that discusses Prothena’s (PRTA) PRX012 having 20-times the potency and plaque reduction of Eisai (ESALY) and Biogen’s (BIIB) lecanemab in reduction of protofibril plaque and being "substantially more potent" than Eli Lilly’s (LLY) donanemab in ex-vivo models. Yee, who calls the data "promising," has a Buy rating on Prothena shares.